inosine-diphosphate and Diabetic-Foot

inosine-diphosphate has been researched along with Diabetic-Foot* in 3 studies

Trials

2 trial(s) available for inosine-diphosphate and Diabetic-Foot

ArticleYear
[EFFICACY OF CYTOFLAVIN IN COMPLEX TREATMENT OF DIABETIC FOOT SYNDROME].
    Georgian medical news, 2017, Issue:265

    The study involved 97 patients with severe diabetic foot syndrome (DFS) subcompensated type 2 diabetes. All patients were available mediacalcification foot and lower leg arteries of different severity. Depending on the treatment, all patients were divided into 2 groups by stratified randomization. The І group received standard therapy, which is indicated for the DFS. A ІІ group of patients additionally received basic therapy drug Cytoflavin 10 ml 0,9% NaCl 200 ml for 10 days, followed by transfer to tablet form Cytoflavin 2 tablets 2 times per day orally for one month. We noted a positive trend of treatment of patients who, in addition to standard therapy received the drug Cytoflavin. Thus, the use of complex surgical treatment of patients with mixed form of DFS Cytoflavin reduces the severity of distal polyneuropathy, improves oxygenation of tissues and restores the enzyme activity of antioxidant system, that manifested neuroprotective, antioxidant and anti-hypoxic effects of drugs, which substantiates the indications for its use in the this pathology.

    Topics: Antioxidants; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Foot; Drug Combinations; Female; Flavin Mononucleotide; Foot; Humans; Inosine Diphosphate; Leg; Male; Monckeberg Medial Calcific Sclerosis; Neuroprotective Agents; Niacinamide; Succinates

2017
[Rationale of application of the drug Cytoflavin in complex treatment of patients with diabetic foot syndrome with mediacalcification arteries].
    Khirurgiia, 2014, Issue:12

    The study involved 60 patients with diabetic foot syndrome (DFS) with severe subcompensated diabetes type II. All patients were available mediacalcification foot and lower leg arteries of different severity. Depending on the treatment, all patients were divided into 2 groups by stratified randomization. The first group received basic therapy that is indicated for DFS which included antibiotics, vessels extending drugs neuroprotective and detoxification facilities. The second group of patients in addition to basic therapy received the drug cytoflavin 10 ml 0.9% NaCl 200 ml for 10 days, followed by transfer to the tablet form cytoflavin 2 tablets 2 times a day orally for 1 month. We noted a positive trend treat patients in addition to standard therapy received the drug cytoflavin, resulting in a marked neuroprotective, antihypoxant and antioxidant effects of the drug. Thus, the use of complex surgical treatment of patients with mixed form DFS cytoflavin reduces the severity of distal polyneuropathy, improves tissue oxygenation and restores the activity of antioxidant enzymes system, manifested a marked neuroprotective, anti-hypoxic and antioxidant effects of drugs and indications to justify its use in this condition.

    Topics: Aged; Anti-Bacterial Agents; Antioxidants; Arteries; Combined Modality Therapy; Debridement; Diabetes Mellitus, Type 2; Diabetic Foot; Drug Combinations; Drug Monitoring; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male; Middle Aged; Neuroprotective Agents; Niacinamide; Peripheral Arterial Disease; Severity of Illness Index; Succinates; Treatment Outcome; Vascular Calcification; Vasodilator Agents

2014

Other Studies

1 other study(ies) available for inosine-diphosphate and Diabetic-Foot

ArticleYear
[THE PHARMACOTHERAPEUTIC EFFICIENCY OF CYTOFLAVIN IN PATIENTS WITH DIABETIC FOOT SYNDROME: IMMEDIATE AND LONG-TERM RESULTS].
    Klinicheskaia meditsina, 2015, Volume: 93, Issue:6

    Immediate and long-term results of parenteral and oral administration of cytoflavin to patients with diabetic foot complicated by grade I and II trophic ulcers (Wagner classification) are considered with special reference to the assessment of reparative processes, normalization of the serum pro oxidant-antioxidant system, and improvement of clinical and instrumental bloodflow characteristics.

    Topics: Adult; Aged; Diabetic Foot; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male; Middle Aged; Neuroprotective Agents; Niacinamide; Succinates; Syndrome; Treatment Outcome

2015